| Style | Citing Format |
|---|---|
| MLA | Salarinia R, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets, vol. 16, no. 9, 2016, pp. 773-788. |
| APA | Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, Nahand JS, Hadjati J, Asrami MO, Fadaei S, Salehi R, Mirzaei H (2016). Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets, 16(9), 773-788. |
| Chicago | Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets 16, no. 9 (2016): 773-788. |
| Harvard | Salarinia R et al. (2016) 'Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies', Current Cancer Drug Targets, 16(9), pp. 773-788. |
| Vancouver | Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, et al.. Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets. 2016;16(9):773-788. |
| BibTex | @article{ author = {Salarinia R and Sahebkar A and Peyvandi M and Mirzaei HR and Jaafari MR and Riahi MM and Ebrahimnejad H and Nahand JS and Hadjati J and Asrami MO and Fadaei S and Salehi R and Mirzaei H}, title = {Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies}, journal = {Current Cancer Drug Targets}, volume = {16}, number = {9}, pages = {773-788}, year = {2016} } |
| RIS | TY - JOUR AU - Salarinia R AU - Sahebkar A AU - Peyvandi M AU - Mirzaei HR AU - Jaafari MR AU - Riahi MM AU - Ebrahimnejad H AU - Nahand JS AU - Hadjati J AU - Asrami MO AU - Fadaei S AU - Salehi R AU - Mirzaei H TI - Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies JO - Current Cancer Drug Targets VL - 16 IS - 9 SP - 773 EP - 788 PY - 2016 ER - |